Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 14, 2021; 27(38): 6489-6500
Published online Oct 14, 2021. doi: 10.3748/wjg.v27.i38.6489
Published online Oct 14, 2021. doi: 10.3748/wjg.v27.i38.6489
Serum soluble suppression of tumorigenicity 2 as a novel inflammatory marker predicts the severity of acute pancreatitis
Yan Zhang, Bo Cheng, Zhong-Wei Wu, Zong-Chao Cui, Yao-Dong Song, San-Yang Chen, Yan-Na Liu, Chang-Ju Zhu, Department of Emergency, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China
Author contributions: Zhu CJ conceived and designed the study; Zhang Y, Cheng B, Liu YN and Wang QF performed the research; Wu ZW contributed the data acquisition; Zhang Y and Cui ZC conducted data analysis/interpretation; Song YD contributed statistical analysis; Zhang Y and Chen SY wrote the manuscript; All authors have read and approved the final manuscript.
Supported by Henan Province Education Department for Henan Province University Key Scientific Research Project , No. 20A320018 and No. 20A320064 .
Institutional review board statement: The study was reviewed and approved by the First Affiliated Hospital of Zhengzhou University Institutional Review Board [(Approval No. 2018-KY-140)].
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors have no potential conflict of interest to disclose.
Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at zhuchangju98@163.com. No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chang-Ju Zhu, PhD, Chief Doctor, Chief Physician, Director, Doctor, Professor, Department of Emergency, the First Affiliated Hospital of Zhengzhou University, No. 1 Eastern Jianshe Road, Zhengzhou 450052, Henan Province, China.
Received: April 4, 2021
Peer-review started: April 4, 2021
First decision: May 27, 2021
Revised: June 10, 2021
Accepted: August 27, 2021
Article in press: August 27, 2021
Published online: October 14, 2021
Processing time: 190 Days and 14.3 Hours
Peer-review started: April 4, 2021
First decision: May 27, 2021
Revised: June 10, 2021
Accepted: August 27, 2021
Article in press: August 27, 2021
Published online: October 14, 2021
Processing time: 190 Days and 14.3 Hours
Core Tip
Core Tip: Acute pancreatitis (AP) is an inflammatory disease in which the regulatory pathway is complex and not well understood. The interleukin (IL)-33/ suppression of tumorigenicity 2L (ST2L) functional pathway is involved in the pathological process of AP. Soluble suppression of tumorigenicity 2 protein (sST2) is a soluble receptor, which is released in the circulation acts as a decoy receptor by binding IL-33. However, sST2 as one of the most promising disease biomarker, has not been studied in the development of AP. In this study we studied the role of sST2 as an inflammatory marker for predicting the severity of acute pancreatitis.